PAO Group, Inc. (PAOG), an Ohio-based biopharmaceutical tech company, has announced that it’s aggressively seeking an international research partnership—specifically, in Israel—to further its progress in cannabis respiratory treatment development.
Israel, also known as “The Land of Milk and Honey,” has been making tremendous strides in the medicinal cannabis sector, particularly in research on the efficacy of cannabis in treating COVID-19 side effects.
PAOG said in a press release, “Israel is recognized as one of the leading cannabis research centers in the world. Parallel to PAOG’s own research on its proprietary cannabis extract for the treatment of COVID-19, a study in Israel was recently released with findings that [terpenes] in cannabis showed efficacy in treating COVID-19.”
“Israel is recognized as one of the leading cannabis research centers in the world. Parallel to PAOG’s own research on its proprietary cannabis extract for the treatment of COVID-19, a study in Israel was recently released with findings that [terpenes] in cannabis showed efficacy in treating COVID-19.”
PAOG offers its RespRX treatment for respiratory disease or infection. This cannabis inhaler administers the company’s patented CBD compound directly into the patient’s lungs.
But after obtaining and patenting the proprietary formulations for the RespRX compound, PAOG hopes to partner with Israeli researchers to improve the formula.
Before the COVID-19 pandemic hit, medical solutions to treat both Chronic Obstructive Pulmonary Disease (COPD) and coronavirus infections weren’t a priority for leading pharmaceutical developers.
Now that the market for COVID-19 solutions has matured, the race to develop a solution is underway. While pharmaceutical giants including Glenmark Pharmaceuticals, GlaxoSmithKline, AstraZeneca, and others scramble to uncover a solution, PAOG is also developing a treatment.
PAOG told The Jerusalem Post, “A paper on the results of the study was published and well-received, given the potential impact on this large market. WHO estimates 65 million people worldwide are afflicted with moderate to severe COPD, and GlobalData forecasts that the COPD treatment market will reach $14.1 billion by 2020.”
Treating existing illnesses that result in wheezing, breathlessness and other lung problems is crucial with COVID-19’s prevalence and potential to spread. Recent research from MedRxiv highlights that patients with these existing problems have a higher chance of developing severe COVID-19 infections.
As COVID-19 poses an elevated threat to patients who already have lung issues, PAOG’s Israeli partnership stands to perfect it’s solution and secure its share of the market.